Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Bio-heart Biological Technology Co., Ltd.
上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

ANNOUNCEMENT PURSUANT TO RULE 13.51B(2) OF THE LISTING RULES

This announcement is made by Shanghai BioHeart Medical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.51B(2) of the Rules Governing the Listing of Securities on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The board of directors of the Company (the "**Board**") was informed by Mr. Chen Yiqing ("**Mr. Chen**"), an independent non-executive director of the Company, that he has received the "Decision on Issuance of Warning Letter to Zhongyuan Concord Cell and Gene Engineering Co., Ltd., Gong Hongjia, Wang Hongqi and Chen Yiqing" (Jin Zheng Jian Cuo Shi [2026] No. 32) issued by the Tianjin Securities Regulatory Bureau of the China Securities Regulatory Commission dated September 14, 2026 (the "**Warning Letter**").

According to the Warning Letter, Zhongyuan Concord Cell and Gene Engineering Co., Ltd* (中源協和細胞基因工程股份有限公司) ("**Zhongyuan Concord**"), a company listed on the Shanghai Stock Exchange (stock code: 600645.SH), was found to be in violation of the Administrative Measures for Information Disclosure of Listed Companies (《上市公司信息披露管理辦法》) issued by the China Securities Regulatory Commission in relation to a related party transaction entered into in July 2025, and Mr. Chen, the then secretary of the board of directors of Zhongyuan Concord failed to perform his duties to Zhongyuan Concord and, together with other named individuals, shall bear the responsibility for the violation. The Warning Letter serves as a supervisory measure on Mr. Chen, which will be recorded in the securities and futures market integrity file.

* *For identification purposes only*

Having considered that (i) the matters covered by the Warning Letter occurred during Mr. Chen's tenure at Zhongyuan Concord, and have no connection with the Group's business, operations, finance or historical information disclosure of the Company; and (ii) during Mr. Chen's service as an independent non-executive director of the Company, he has performed his duties diligently and there are no information disclosure violations or circumstances harming the interests of the Company and its shareholders in relation to the Company; the Board (other than Mr. Chen) is of the view that the Warning Letter will not affect Mr. Chen's suitability to act as an independent non-executive director of the Company.

As disclosed in the announcement of the Company dated August 26, 2026, Mr. Chen has tendered his resignation as an independent non-executive director of the Company on August 26, 2026, and will continue to perform his duties as an independent non-executive director of the Company until the date when the appointment of the new independent non-executive director is approved by the shareholders of the Company.

Based on the above, the Board (other than Mr. Chen) considers that the matter of Mr. Chen receiving the Warning Letter will not have any material adverse impact on the Group's operations, financial position or business development.

Save as disclosed in this announcement, there is no information about Mr. Chen that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and there are no matters about Mr. Chen that need to be brought to the attention of the shareholders of the Company.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and Executive Director

Shanghai, the People's Republic of China, September 16, 2026

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive Director, Mr. Yunqing WANG and Ms. Peili WANG as executive Directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive Directors.